Bisphosphonates for cardiovascular risk reduction: A systematic review and meta-analysis
Guido Kranenburg1, Jonas W Bartstra1, Maaike Weijmans1
1Department of Vascular Medicine, University Medical Center Utrecht, The Netherlands.
Insights
Bisphosphonates reduce arterial calcification but do not impact cardiovascular events. However, they may lower cardiovascular and all-cause mortality, offering potential benefits across patient groups.
Area of Science:
- Cardiovascular Research
- Pharmacology
- Medical Interventions
Background:
- Bisphosphonates are investigated for their potential to reduce cardiovascular events by inhibiting arterial calcification.
- Atherosclerotic processes and cardiovascular disease prevention are key areas of concern.
Purpose of the Study:
- To investigate the effects of bisphosphonate treatment on preventing atherosclerotic processes.
- To evaluate the impact of bisphosphonates on cardiovascular disease outcomes.
Main Methods:
- Systematic review of randomized controlled studies from Pubmed, Embase, and Cochrane Library up to January 2016.
- Inclusion of 61 trials assessing bisphosphonates' effects on arterial wall disease, cardiovascular events, and mortality.
- Use of random-effects models for pooled estimate calculations.
Main Results:
- Bisphosphonates significantly reduced arterial calcification ( -11.52% difference).
- No significant effect was observed on arterial stiffness or cardiovascular events.
- A trend towards reduced cardiovascular mortality (RR 0.81) and a significant reduction in all-cause mortality (RR 0.90) were noted.
Conclusions:
- Bisphosphonates effectively reduce arterial wall calcification but do not influence arterial stiffness or cardiovascular events.
- Bisphosphonates show a tendency to reduce cardiovascular mortality and significantly reduce all-cause mortality.
- These benefits were observed in diverse patient populations, including those with osteoporosis and cancer.
Background And Aims:
Bisphosphonates might be effective in reducing cardiovascular events due to their ability to reduce calcification in arterial walls. We aimed to investigate the effects of treatment with bisphosphonates on the prevention of atherosclerotic processes and cardiovascular disease.
Methods:
Pubmed, Embase and the Cochrane Library were systematically reviewed by two independent investigators for randomized controlled studies published up to January 2016, in which the effect of bisphosphonates on arterial wall disease, cardiovascular events, cardiovascular mortality or all-cause mortality were reported. There was no restriction for the type of population used in the trials. Random-effects models were used to calculate the pooled estimates.
Results:
61 trials reporting the effects of bisphosphonates on the outcomes of interest were included. Bisphosphonates had beneficial effects on arterial wall disease regarding arterial calcification (pooled mean percentage difference of 2 trials -11.52 (95% CI -16.51 to -6.52, p < 0.01, I(2) 13%), but not on arterial stiffness (pooled mean percentage difference of 2 trials -2.82; 95% CI -10.71-5.07; p = 0.48, I(2) 59%). No effect of bisphosphonate treatment on cardiovascular events was found (pooled RR of 20 trials 1.03; 95% CI 0.91-1.17, I(2) 16%), while a lower risk for cardiovascular mortality was observed in patients treated with bisphosphonates (pooled RR of 10 trials 0.81; 95% CI 0.64-1.02; I(2) 0%) although not statistically significant. Patients treated with bisphosphonates had a reduced risk of all-cause mortality (pooled RR of 48 trials 0.90; 95% CI 0.84-0.98; I(2) 53%).
Conclusions:
In this systematic review and meta-analysis it is shown that bisphosphonates reduce arterial wall calcification but have no effect on arterial stiffness or on cardiovascular events. Bisphosphonates tend to reduce the risk of cardiovascular mortality and reduce all-cause mortality in various patient groups, including osteoporosis and cancer patients.
Related Concept Videos
01:26Atherosclerosis III: Management
01:27Coronary Artery Disease V: Interprofessional Care
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...